drugset
drugset / Trial / NCT01931046

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

NCT01931046 ↗

Phase 1/2 Completed 28 enrolled Momotaro-Gene Inc. The Pacific Link Consulting Co · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.

Timeline

Start
2013-10
Primary completion
2018-07-06
Completion
2020-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad5-SGE-REIC/Dkk3 Unknown — Other

Indications

cancer